First Trial of CRISPR-Edited T cells in Lung Cancer.

  title={First Trial of CRISPR-Edited T cells in Lung Cancer.},
  author={Simon F. Lacey and Joseph A. Fraietta},
  journal={Trends in molecular medicine},
The clinical application of CRISPR-Cas9 gene editing has been eagerly awaited since the first description of the technique in 2013. Lu and colleagues now describe the treatment of 12 patients with nonsmall-cell lung cancer (NSCLC) with PD-1 gene-edited bulk autologous T cells, with results supporting both the feasibility and safety of gene editing in cell therapy. 
2 Citations
Targeting Cancer with CRISPR/Cas9-Based Therapy
Recent advancements in cancer-selective treatments based on the CRISPR/Cas9 system are described, especially focusing on strategies for targeted delivery of the CRisPR/cas9 machinery to affected cells, controlling Cas9 expression in tissues of interest and disrupting cancer-specific genes to result in selective death of malignant cells.


Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer
In a first-in-human phase I trial of patients with advanced lung cancer, infusions of autologous T cells edited to delete the PD-1 gene via CRISPR–Cas9 were well tolerated and did not lead to severe treatment-related adverse events.
CRISPR-engineered T cells in patients with refractory cancer
This first-in-human, phase 1 clinical trial was designed to test the safety and feasibility of multiplex CRISPR-Cas9 gene editing of T cells from patients with advanced, refractory cancer and found the persistence of the T cells expressing the engineered TCR was much more durable than in three previous clinical trials during which T cells were infused.
CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia.
Although this study transplanted CRISPR-edited CCR5-ablated hematopoietic stem and progenitor cells (HSPCs) into a patient with HIV-1 infection and acute lymphoblastic leukemia, the percentage of C CR5 disruption in lymphocytes was only approximately 5%, which indicates the need for further research into this approach.
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
By using gene editing to simultaneously introduce the CAR and disrupt TCR and CD52 in T cells, the authors generated functional CAR T cells that could evade host immunity for use in unmatched recipients and demonstrates the therapeutic potential of gene-editing technology.
iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity
An improvement of the GUIDE-seq method, iGUIDE, is reported, which allows filtering of mispriming events to clarify the true cleavage signal and specifies the locations of Cas9-guided cleavage for four guide RNAs.